Attached files

file filename
EX-99.1 - PDF OF SUBMISSION - WaferGen Bio-systems, Inc.submissionpdf.pdf
EX-99.1 - PRESS RELEASE FOR 3RD QUARTER 2011 - WaferGen Bio-systems, Inc.ex_99-1.htm


 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 21, 2011


 
WaferGen Bio-systems, Inc.
 
 
(Exact Name of Registrant as Specified in its Charter)
 

 
Nevada
 
000-53252
 
90-0416683
 
 
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 

 
7400 Paseo Padre Parkway, Fremont, CA
 
94555
 
 
(Address of principal executive offices)
 
(Zip Code)
 

(Registrant’s telephone number, including area code):  (510) 651-4450

Not Applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))







 
 

 



Item 2.02. Results of Operations and Financial Condition.

On November 21, 2011, WaferGen Bio-systems, Inc. issued a press release announcing its financial results for the third quarter of the year ending December 31, 2011.  The full text of the press release is furnished hereto as Exhibit 99.1.


Item 9.01. Financial Statements and Exhibits.

(d)       Exhibits.

Exhibit No.
 
Description
     
 
Press release issued on November 21, 2011.


 
2

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
WaferGen Bio-systems, Inc.
 
Date: November 21, 2011
By:
/s/ Don Huffman
   
Don Huffman
   
Office of the President and Chief Financial Officer

 
3